For your patients rss

ERAS leads to reduced length of stay for geriatric joint replacement patients(0)

January 1, 2020

The results of a quality improvement initiative to reduce length of stay for arthroplasty patients at the Kaiser Westside Medical Center (KWMC), Hillsboro, OR, are summarized.


Modified FOLFIRINOX is superior to gemcitabine as adjuvant therapy for resected pancreatic cancer: The PRODIGE 24/CCTG PA6 Trial

The study design and findings of the PRODIGE 24/CCTG PA6 Trial are outlined, which showed improved survival with modified FOLFIRINOX for resected pancreatic cancer patients.

Figure 1. Outcomes comparison, pre-ERAS vs. ERAS

ERAS program improves outcomes in patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy

The Mayo Clinic in Arizona, Phoenix, implemented an enhanced recovery after surgery program for patients undergoing hyperthermic intraperitoneal chemotherapy, and the results and lessons learned are described.

Figure 1. Schema: ALCHEMIST CHEMO-IO

ALCHEMIST trial has potential to improve outcomes after lung cancer resection

The ALCHEMIST CHEMO-IO is a trial for patients with early-stage non-small cell lung cancer (NSCLC) with the potential to change the way patients with resected NSCLC are treated.

Figure 4. Percent of astrocytoma and glioblastoma by sex for NCDB and CBTRUS in 2006–2010 and 2011–2015

Comparison of NCDB and CBTRUS demographic data for astrocytoma and glioblastoma

This article compares demographic data of astrocytomas and glioblastomas patients documented in the NCDB, a hospital-based cancer registry, with cases in the Central Brain Tumor Registry of the U.S.

More in this category

« Older Posts   


Bulletin of the American College of Surgeons
633 N. Saint Clair St.
Chicago, IL 60611


Download the Bulletin App

Apple Store
Get it on Google Play
Amazon store